Biopharma & Life Sciences
Altimmune Executive Compensation (FY25)
ALT · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): April 16, 2026
210 figures on this page: 200 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
The disclosed peer group names 89bio, Inc., Akero Therapeutics, Inc., Amylyx Pharmaceuticals, Inc., Anavex Life Sciences Corp. and Arbutus Biopharma Corporation, among others. Meanwhile, Vipin Garg, Chief Executive Officer, received $8,026,590 in total compensation for fiscal 2025, and Garg's total moved 31.8% higher from the $6,090,462 reported for fiscal 2024, and the say-on-pay proposal drew 76.8% support at the meeting held April 16, 2026 for fiscal 2025. For fiscal 2025, the company reported 4 named executive officers.
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vipin Garg: $6,090,462 → $8,026,590 (31.8% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Altimmune's chief executive and what were they paid?
Vipin Garg, Chief Executive Officer, received $8,026,590 in total compensation for fiscal 2025. Garg's total moved 31.8% higher from the $6,090,462 reported for fiscal 2024.
What was Altimmune's say-on-pay result?
The say-on-pay proposal drew 76.8% support at the meeting held April 16, 2026 for fiscal 2025.
Which companies are in Altimmune's peer group?
The disclosed peer group names 89bio, Inc., Akero Therapeutics, Inc., Amylyx Pharmaceuticals, Inc., Anavex Life Sciences Corp. and Arbutus Biopharma Corporation, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Vipin Garg Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
M. Scott Harris former Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
M. Scot Roberts Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Vipin Garg Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
M. Scott Harris former Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christophe Arbet-Engels Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
M. Scot Roberts Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Christophe Arbet-Engels | Option | — | — | — | — | — | — | ◇ |
| Christophe Arbet-Engels | RSU | — | — | — | — | — | — | ◇ |
| Dr. Sohn | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Durso | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Durso | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| M. Scot Roberts | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| M. Scot Roberts | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| M. Scott Harris | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| M. Scott Harris | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Vipin Garg | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Vipin Garg | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| M. Harris | Option | ◇ | — | ◇ | 2/2/2032 |
| Option | ◇ | — | ◇ | 1/30/2033 | |
| Option | ◇ | — | ◇ | 1/27/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/25/2034 | |
| RSU | ◇ | ◇ | — | — | |
| M. Roberts | Option | ◇ | — | ◇ | 1/30/2033 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/27/2035 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/25/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Vipin Garg | Option | ◇ | — | ◇ | 1/30/2033 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/25/2034 | |
| Option | ◇ | — | ◇ | 1/27/2035 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| Christophe Arbet-Engels | Option | ◇ | — | ◇ | 10/1/2035 |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Jerome Durso Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Catherine Sohn, Pharm D | ◇ | — | ◇ | — | — | — | ◇ |
Philip L. Hodges | ◇ | — | ◇ | — | — | — | ◇ |
Wayne Pisano | ◇ | — | ◇ | — | — | — | ◇ |
Mitchel Sayare, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
John M. Gill | ◇ | — | ◇ | — | — | — | ◇ |
Klaus O. Schafer, M.D., MPH | ◇ | — | ◇ | — | — | — | ◇ |
Diane K. Jorkasky, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Teri Lawver | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 89bio, Inc. ETNB
- Akero Therapeutics, Inc. AKRO
- Amylyx Pharmaceuticals, Inc. AMLX
- Anavex Life Sciences Corp. AVXL
- Arbutus Biopharma Corporation ABUS
- Arcturus Therapeutics Holdings Inc. ARCT
- Astria Therapeutics, Inc. ATXS
- Atea Pharmaceuticals, Inc. AVIR
- aTyr Pharma, Inc. ATYR
- Gossamer Bio, Inc. GOSS
- Inhibrx Biosciences, Inc. INBX
- MBX Biosciences, Inc. MBX
- Rezolute, Inc. RZLT
- Savara Inc. SVRA
- Solid Biosciences Inc. SLDB
- Terns Pharmaceuticals, Inc. TERN
- Tyra Biosciences, Inc. TYRA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | April 16, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | September 25, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | September 26, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | September 28, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | September 29, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | September 23, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | September 24, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | September 26, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | August 30, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | October 13, 2017 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Altimmune disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Altimmune sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
210 figures on this page: 200 cited to the filing that reported them, 10 calculated from figures it prints.
200 cited to the filing
10 calculated from the filing
Documents cited
- 0001326190-26-000027Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-26-028953Director Compensation · Director Compensation for Fiscal Year 2025 · ELECTION OF DIRECTORS · EXECUTIVE COMPENSATION · and 2 more sections
- 0001326190-25-000050Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001326190-25-000046Summary Compensation Table
- 0001326190-24-000042Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001326190-23-000040Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001326190-22-000007Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-21-119390Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-254566Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-259847Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-18-265020Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-312751Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Altimmune executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/ALT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Altimmune and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Altimmune discloses
The companies named in ALT's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}